Michael Lloyd is a Cardiology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1301 W 12th Ave Ste 207
Emporia, KS 66801
Telephone
620-343-6800Registry record last updated 14 May 2019.
Clinical trials
- Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
Sponsor: Boston Scientific Corporation
- Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Sponsor: Michael S. Lloyd
- RF Lesion Monitoring With 8mm IntellaTip MiFi XP
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202524 payments
- Novartis Pharmaceuticals CorporationProgram year202527 payments
- Amgen Inc.Program year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
77.3%Beta blocker23.7%Carvedilol36%Metoprolol Succinate29%Metoprolol Tartrate25%Atenolol5%Labetalol Hcl3%Sotalol3%Part D<11 patientsStatin8.8%Atorvastatin Calcium56%Rosuvastatin Calcium39%Pravastatin Sodium6%Part D<11 patients+ 16 more classes in this area
Blood & clotting
14.6%Factor Xa inhibitor9.7%Eliquis58%Xarelto42%Part D≥36 patientsP2Y12 inhibitor4.9%Clopidogrel90%Brilinta10%Part D<11 patientsMetabolism & gastrointestinal
6.6%Potassium supplement2.6%Potassium Chloride100%Part D≥22 patientsProton pump inhibitor2.2%Pantoprazole Sodium71%Omeprazole29%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”